Silence Therapeutics reported QQ3 2024 results that feature a modest quarterly revenue uptick but continued steep operating losses and a heavy research and development (R&D) burden. Revenue rose to GBP 1.142 million in the quarter, up 90.97% QoQ from Q2 2024 (GBP 0.598 million), yet remained down roughly 59% versus the year-ago quarter (GBP 2.798 million in Q3 2023). The quarter generated a negative gross profit of GBP 1.632 million, reflecting an unfavorable gross margin of -1.43%, as the company continues to invest aggressively in its RNAi discovery platform and pipeline. Operating and net results remained deeply negative: operating loss of GBP 22.537 million and net loss of GBP 27.012 million for QQ3 2024, with EPS of -0.57.
Cash flow and liquidity remain a relative strength. Silence closed QQ3 2024 with GBP 61.95 million in cash and cash equivalents and GBP 67.04 million in short-term investments, yielding total cash and short-term investments of GBP 128.99 million. The company reports a net cash position of approximately GBP -61.81 million (net cash), highlighting robust liquidity with no material long-term debt. Cash flow from operations was negative at GBP -27.21 million for the quarter, driven by the operating burn and investments, while free cash flow remained negative at GBP -19.70 million. The balance sheet shows a solid current ratio (~6.96x) and a debt-to-equity profile of essentially zero leverage, underpinned by a diversified collaboration-based revenue model rather than product sales.
Strategically, Silencecontinues to advance its two Phase I programs, SLN360 (cardiovascular risk reduction) and SLN124 (hematologic indications), and maintains collaboration agreements with AstraZeneca, Mallinckrodt IP Trading DAC, and Hansoh Pharmaceutical Group. While there is no formal forward-looking guidance in the provided data, management commentary around trial progression, milestone payments, and collaboration leverage will be critical catalysts for 2025. The current setup—strong liquidity, meaningful R&D investment, and potential milestone-driven upside from partnerships—constitutes a high-risk, high-reward investment profile typical of early-stage biotech pipelines.